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Abstract: Diseases associated with acquired or genetic defects in members of the chaperoning system
(CS) are increasingly found and have been collectively termed chaperonopathies. Illustrative instances
of genetic chaperonopathies involve the genes for chaperonins of Groups I (e.g., Heat shock protein 60,
Hsp60) and II (e.g., Chaperonin Containing T-Complex polypeptide 1, CCT). Examples of the former
are hypomyelinating leukodystrophy 4 (HLD4 or MitCHAP60) and hereditary spastic paraplegia
(SPG13). A distal sensory mutilating neuropathy has been linked to a mutation [p.(His147Arg)] in
subunit 5 of the CCT5 gene. Here, we describe a new possibly pathogenic variant [p.(Leu224Val)] of
the same subunit but with a different phenotype. This yet undescribed disease affects a girl with
early onset demyelinating neuropathy and a severe motor disability. By whole exome sequencing
(WES), we identified a homozygous CCT5 c.670C>G p.(Leu224Val) variant in the CCT5 gene. In
silico 3D-structure analysis and bioinformatics indicated that this variant could undergo abnormal
conformation and could be pathogenic. We compared the patient’s clinical, neurophysiological and
laboratory data with those from patients carrying p.(His147Arg) in the equatorial domain. Our patient
presented signs and symptoms absent in the p.(His147Arg) cases. Molecular dynamics simulation
and modelling showed that the Leu224Val mutation that occurs in the CCT5 intermediate domain
near the apical domain induces a conformational change in the latter. Noteworthy is the striking
difference between the phenotypes putatively linked to mutations in the same CCT subunit but
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located in different structural domains, offering a unique opportunity for elucidating their distinctive
roles in health and disease
Keywords: CCT5; chaperonins; chaperoning system; genetic variants; mutation; genetic
chaperonopathies; motor neuropathy
1. Introduction
Molecular chaperones (chaperones in short) are important components of all living cells in
which they play a variety of roles. Canonical functions include assisting protein folding and refolding,
translocation of proteins through membranes, ushering proteins damaged beyond repair to degradation,
dissolution of protein aggregates, and selective autophagy. Chaperones perform protein quality control
checks, essential for the maintenance of protein homeostasis [1]. Many chaperones belong to the
category of “heat shock proteins” (Hsps), although not all Hsps are chaperones, and not all chaperones
are Hsps (these terms are often used interchangeably). Chaperones are classified following several
criteria, the most useful being their apparent molecular weight. Chaperones usually work in multimeric
complexes, forming homo- or hetero-oligomeric teams, which associate with other molecules to build
functional networks [1].
The term chaperonin is applied to members of a set of 55–64 kDa chaperones represented in
humans by two groups: The mitochondrial Hsp60 (Cpn60, Group I) and the cytosolic chaperonin
containing TCP-1 subunit (CCT, Group II).
A structurally and/or functionally defective chaperone is often associated with diseases, collectively
termed “chaperonopathies”. Most of the hereditary chaperonopathies studied thus far tend to appear
early in life and affect various tissues and organs, such as the central and peripheral nervous systems
and the cardiocirculatory apparatus [2].
Chaperonopathies can be divided into categories, based on the chaperone gene-protein involved.
Chaperonopathies due to mutations in small-size chaperones (sHsps) involve genes encoding
chaperones with a MW 34 kDa or less, such as the crystallin subgroup; tissues affected are the eye
lens, voluntary muscles, and peripheral nerves. Chaperonopathies due to mutations in the chaperonin
genes involve Hsp60 (Cpn60), which causes hereditary spastic paraplegia (SPG13, MIM605280)
and MitCHAP-60 disease (Pelizaeus-Merzbacher-like, MIM612233). In Group II, MKKS causes the
McKusick-Kaufman syndrome characterized by genitourinary malformations (MIM#236700), and
BBS10, and BBS12 Bardet-Biedl syndromes (BBS) type 10 (MIM # 615987) and 12 (MIM # 615989) [1]. A
CCT5 gene mutation is associated with a human phenotype, i.e., a mutilating, distal sensory neuropathy
with severe atrophy of the posterior tract of the spinal cord [3,4]. Diseases associated with mutations
in the genes encoding proteins within the Hsp40 and Hsp70 families, as well in the gene encoding the
very large chaperone, sacsin have been described associated with a variety of neurologic disorders [2,5].
Here, we report a novel c.670C>G p.(Leu224Val) variant in CCT5 that is likely associated with
a disease characterized by early onset demyelinating motor neuropathy, expanding the range of
phenotypes associated with this gene [3,4].
2. Results
2.1. Clinical History
The proband was a macrosomic female newborn (birthweight 4500 g, 100th centile; length 52 cm,
93rd centile) born at term with eutocic delivery and good neonatal adaptation after an uneventful
pregnancy. She was the first child of consanguineous first cousins (Figure 1A) with a positive family
history for metabolic disorders.
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Figure 1. Pedigree (A) and genetic analyses (B). Whole exome sequencing identified a homozygous 
missense variant in exon 5 of CCT5 c.670C>G p.(Leu224Val) (NM_012073). Leucine 224 is 
evolutionarily conserved from yeasts to vertebrates (C), each color corresponds to a single specific 
amino acid. 
A second cousin died at two years of age probably due to mitochondrial disease. Until eight 
months of age, she had a slow but otherwise normal neuro-psychomotor development. Later, her 
parents noted progressive hypotonia, developmental arrest and regression of sensorimotor and 
cognitive abilities. She presented difficulties getting to an upright position and was unable to walk 
without support showing a general progressive hyposthenia. After a few months, she presented with 
dystonic crises with extrapyramidal hypertonia, dystonic posturing of the extremities, fine tremors, 
and up-rolling of the eyes suggestive of seizures. 
Electro-encephalogram (EEG) revealed a disorganized brain electrical activity, with theta and 
delta activity on left temporo-occipital derivations, and an asymmetric pattern consistent with the 
presence of clinical signs of generalized seizures. Brain magnetic resonance imaging (MRI) showed a 
mild delay of white matter myelination of the posterior regions. She was started on antiepileptic 
medications (clonazepam and trihexyphenidyl) and rehabilitation treatment with only partial 
response. 
At two years of age, she was still unable to walk, to sit unsupported, to roll over, or voluntarily 
control sphincter function. She showed subsequent progressive worsening of dystonic crises 
(carbamazepine and haloperidol were included in the therapeutic scheme), neuronal impairment and 
muscular involvement with severe hypotonia and feeding problems (poor suck, swallowing 
difficulties, gastroesophageal reflux) leading to failure to thrive and requiring surgical management 
(Nissen fundoplication and PEG placement) at three years of age. Expressive language was absent. 
A prominent jaw dystonia hampered to fully close her mouth and produce normal speech. 
Intelligence quotient showed severe impairment. In the following months, a progressive worsening 
of dystonic crises was complicated by dyspnea, fever, and acute respiratory failure requiring 
intubation and mechanical ventilation. A failure to wean from mechanical ventilation led to 
tracheostomy at three and half years of age. Several hospital admissions followed, because of 
recurrent respiratory crises, worsening of hypotonia, severe respiratory acidosis, electrolyte 
disorders and anemia. Levetiracetam and phenobarbital have been introduced in the therapeutic 
scheme with poor results. 
Main metabolic investigations gave normal results: organic acids, carnitine, congenital 
glycosylation disorders, very long chain fatty acid (VLCFA), full plasma amino acid profile, purine 
and pyrimidine, serum lactate, ammonia, glycemia, beta galactosidase, and transaminases (Table S1). 
EEGs at four years of age revealed disorganization of bioelectrical activity, irregular background 
rhythm characterized by slow diffuse waves, high voltage delta waves prevalent in posterior head 
regions, absence of physiological figures of sleep, presence of rapid pharmacological activity. Chest 
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i se variant in exon 5 of CCT5 c.670C>G p.(Leu224Val) (NM_012073). Leucine 224 is evolutionarily
conserved from yeasts to vertebrate (C), each color corresponds to a single specific amino acid.
A second cousin died at two years of age probably due to mitochondrial disease. Until eight
months of age, she had a slow but otherwise normal neuro-psychomotor development. Later, her
parents noted progressive hypotonia, developmental arrest and regression of sensorimotor and
cognitive abilities. She presented difficulties getting to an upright position and was unable to walk
without support showing a general progressive hyposthenia. After a few months, she presented with
dystonic crises with extrapyramidal hypertonia, dystonic posturing of the extremities, fine tremors,
and up-rolling of the eyes suggestive of seizures.
Electro-encephalogram (EEG) revealed a disorganized brain electrical activity, with theta and delta
activity on left temporo-occipital derivations, and an asymmetric pattern consistent with the presence
of clinical signs of generalized seizures. Brain magnetic resonance imaging (MRI) showed a mild delay
of white matter myelination of the posterior regions. She was started on antiepileptic medications
(clonazepam and trihexyphenidyl) and rehabilitation treatment with only partial response.
At two years of age, she was still unable to walk, to sit unsupported, to roll over, or voluntarily
control sphincter function. She showed subsequent progressive worsening of dystonic crises
(carbamazepine and haloperidol were included in the therapeutic scheme), neuronal impairment
and muscular involvement with severe hypotonia and feeding problems (poor suck, swallowing
difficulties, gastroesophageal reflux) leading to failure to thrive and requiring surgical management
(Nissen fundoplication and PEG placement) at three years of age. Expressive language was absent. A
prominent jaw dystonia hampered to fully close her mouth and produce normal speech. Intelligence
quotient showed severe impairment. In the following months, a progressive worsening of dystonic
crises was complicated by dyspnea, fever, and acute respiratory failure requiring intubation and
mechanical ventilation. A failure to wean from mechanical ventilation led to tracheostomy at three
and half years of age. Several hospital admissions followed, because of recurrent respiratory crises,
worsening of hypotonia, severe respiratory acidosis, electrolyte disorders and anemia. Levetiracetam
and phenobarbital have been introduced in the therapeutic scheme with poor results.
Main metabolic investigations gave normal results: organic acids, carnitine, congenital
glycosylation disorders, very long chain fatty acid (VLCFA), full plasma amino acid profile, purine and
pyri idine, serum lactate, ammonia, glycemia, beta galactosidase, and transaminases (Table S1).
EEGs at four years of age revealed disorganization of bioelectrical activity, irregular background
rhythm characterized by slow diffuse waves, high voltage delta waves prevalent in posterior head
regions, absence of physiological figures of sleep, presence of rapid pharmacological activity. Chest
X rays and orthopedic consultancy revealed lumbar spine scoliosis, related to severe hypotonia and
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postural effect. Brain MRI revealed thin corpus callosum, signs of ventricular enlargement and a
pattern of diffuse hyperintensity of cerebral white matter, consistent with diffuse hypo/demyelination,
enlargement of sulci and subarachnoid spaces mainly in the frontal and parietal areas.
We first met the patient at four years of age; her weight was 15 kg (25th centile), her length 93 cm
(third centile) and her head circumference 47.5 cm (third centile). She presented with microcephaly,
severe psychomotor delay and hypotonia, absence of language and any other expressive patterns,
absence of sphincter function control.
Follow-up at seven years of age confirmed the growth pattern (30th centile for weight, sixth centile
for length, second centile for head circumference) and the clinical picture of severe psychomotor delay
and hypotonia without evidence of specific dysmorphic features (Figure 2; Tables 1 and 2, and Table S1
(with: biochemical data for both mutations).
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Table 1. Clinical data for CCT5 variants. 
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Dystonic crisis with extrapyramidal hypertonia, 
dystonic posturing of the extremities, fine tremors, 
and up-rolling of the eyes suggestive of seizures. 
Absent eye contact, horizontal nystagmus, tetra 
paresis, marked axial and segmental hypotonia, 
incomplete head control. 
Spasticity in walking with legs in form of 
X. 
Increased tendon reflexes with ankle 
clonus, Babinsky sign, and discreet distal 
amyotrophy. 
Normal motor function. 
Sensory loss for all modalities in both 
upper and lower limbs, particularly in 
foot. 




Progressive worsening of dystonic crisis with 
neuronal impairment. 
Severe hypotonia and feeding problems (poor suck, 
swallowing difficulties, gastroesophageal reflux). 
Difficulties getting an upright position and inability to 
walk. 
Dyspnea, fever, and acute respiratory failure. 
Absence of sphincter function control. 
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hands and osteomyelitis of the feet leading 
to amputation of his two legs up to the 
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Table 1. Clinical data for CCT5 variants.
Leu224Val His147Arg 1
Gender; Age F mal ; 8 years. ; , 22, 19, and 7 years.
Age at onset Eight months of age. Early infancy, range from 1 to 5 years.
ajor clinical signs and
symptoms
Progressive hypotonia and hyposthenia.
Absent osteotendinous reflexes.
Bilateral clon s of the foot.
Dystonic c isis with extrapyramidal hypertonia,
dystonic posturing of the extremities, fine
tremors, and up-rolling of the eyes suggestive
of seizures.
Absent eye contact, horizontal nystagmus, tetra
paresis, marked axial and segmental hypotonia,
incomplete head control.
Spasticity in walking with legs in form of X.
Increased t ndo reflexes with ankle clonus,
Babi sky sign, and discreet distal amyotrophy.
Normal motor function.
Sensory loss for all modalities in both upper
and lower limbs, particularly in foot.




Progressive worsening of dystonic crisis with
neuronal impairment.
Sever hypotonia and feedi g p oblems (poor
suck, swallowing difficulti s, gastroesophageal
reflux). Difficulties getting an upright position
and inability to walk.
Dyspnea, fever, and acute respiratory failure.
Absence of sphincter function control.
Expressive language absent.
Jaw dystoni .
Severe im airment of intelligence quotient.
Oldest patient: scars of healed ulcers in hands
and osteomyelitis of the feet leading to
amputation of his two legs up to the thighs.
1 Data from references [3,4] (Bouhouche et al., 2006a,b).
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Table 2. Neurophysiological and laboratory data for both mutations.
Data Source Leu224Val His147Arg 1
MRI 2
Mild delay of white matter myelination
of the posterior regions. Thin corpus
callosum, signs of ventricular
enlargement and a pattern of diffuse
hyperintensity of cerebral white matter,
consistent with diffuse
hypo/demyelination, enlargement of
sulci and subarachnoid spaces mainly in
the frontal and parietal areas.




Disorganized brain electrical activity,
with theta and delta activity on left
temporo-occipital derivations.
Asymmetric pattern (generalized
seizures). Irregular background rhythm
characterized by slow diffuse waves;
high voltage delta waves prevalent in
posterior head regions. Absence of
physiological figures of sleep. Presence
of rapid pharmacological activity.
Not reported
Motor nerve conduction
studies (see also Table 3)
Signs of both axonal and demyelinating
motor neuropathy upon stimulation of
the median and peroneal nerve.
Presence of reduced motor amplitude
and delayed motor latency responses
after stimulation of distal sites of the
median and peroneal nerves. No
compound motor evoked potentials
were elicited by stimulation of
proximal nerve sites.
Normal or slightly reduced motor
conduction velocity of the median
and the peroneal nerves.
Motor evoked potentials
(see also Table 3)
Absent motor evoked potentials
following cortical stimulation in either
the APB or TA muscles.
Not reported
Ultrasound scanning Normal cardiac, renal, hepatic, andurogenital ultrasound results. Not reported.
X-rays Chest X rays, lumbar spine scoliosis. Not reported
Karyotype Normal Not reported
Array CGH Normal Not reported
Biochemical measurements
(see also Table S1).
Normal levels of Apo B lipoprotein,
total cholesterol, and triglycerides.
Other: normal values of organic acids,
carnitine, congenital glycosylation
disorders, VLCFA, full plasma amino
acid profile, purine and pyrimidine,
serum lactate, ammonia, glycemia, beta
galactosidase and transaminases.
Decreased levels of Apo B
lipoprotein, total cholesterol, and
triglycerides. Other: not reported.
1 Data from references [3,4] (Bouhouche et al., 2006a,b). 2 Abbreviations: MRI, Magnetic resonance imaging; EEG,
electroencephalogram; APB, abductor pollicis brevis; TA, tibialis anterior; CGH, comparative genomic hybridization
(for microarray-based comparative genomic hybridization).
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2.2. Neurological Examination and Electrophysiological Findings
At seven years of age, neurological examination revealed absent eye contact, horizontal nystagmus
with episodic up-rolling of the eyes, tetraparesis, bilateral foot drop, marked axial and segmental
hypotonia, incomplete head control and need to sit with support (Tables 1 and 2). Osteotendinous
reflexes were absent. Bilateral clonus of the foot was elicited following brisk stretching of the ankle.
The clonus was sporadically accompanied by stiffening of the arms for 1–2 s.
2.3. Motor Evoked Potentials
Motor evoked potentials were absent following cortical stimulation in either the APB or TA
muscles, Table 3. This pattern is consistent with impairment of the motor system, without a clear
distinction between central and peripheral nervous system impairments.
2.4. Motor Nerve Conduction Study
Motor nerve conduction studies of the median and peroneal nerves showed signs of axonal and
demyelinating neuropathy, with the presence of reduced motor amplitude and delayed motor latency
responses after stimulation of distal sites of the median and peroneal nerves, Table 3. No compound
motor evoked potentials were elicited by stimulation of proximal nerve sites.
2.5. Laboratory Investigations and Genetic Analyses
All routine laboratory biochemical investigations and metabolic studies were normal (full plasma
amino acid profile, serum lactate, and ammonia). Cardiac, renal, hepatic, and urogenital ultrasound
investigations were normal. Karyotype and array-CGH analysis performed on peripheral blood
leukocytes were normal.
WES analysis identified 20 homozygous variants with an allele frequency equal to that found
among controls < 0.01. Ten of these had a CADD score > 15. We further studied these genes, excluding
eight variants associated with a class 2 or 3 ACMG (likely benign or VUS) in genes which are not
associated to any known phenotype. A homozygous variant in KIF7, associated with Acrocallosal
syndrome/Joubert syndrome 12 (MIM # 200990) was excluded because it is classified as likely benign.
We also found the homozygous c.670C>G; p.(Leu224Val) in CCT5 (NM_012073), which qualified as the
only possible pathogenic variant by prioritization (Table S2, Figure 1).
Genotyping of maternal and paternal DNAs confirmed the variant at the heterozygous state in both,
according to the recessive pattern of inheritance (Figure 1). CCT5 c.670C>G is reported at a low allele
frequency among controls compatible with a rare recessive disease (5/251,400, rs925661175; GnomAD
ver 2.1.1). Bioinformatics analyses showed the variant is predicted as deleterious by the majority of
softwares (83% in Varsome, aug 2020), with a global domain-adversarial neural network (DANN) score
of 0.9953, and a combined annotation-dependent depletion (CADD) score of 23.0 (PMID 25338716,
30371827.) The leucine 224 is highly conserved in evolution: the Vertebrate Multiz Alignment &
Conservation (100 Species) track at UCSC genome browser (https://genome-euro.ucsc.edu/index.html)
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shows a complete identity among available vertebrate species. Sequence alignment of distantly related
organisms up to S. pombe confirms a high conservation (Figure 1), supporting a key role for this amino
acid in this position in protein function. Nevertheless, based on the rules of the American College
of Medical Genetics and Genomics (ACMG) [6], the c.670C>G p.(Leu224Val) was classified as of
uncertain significance.
2.6. Molecular Dynamics Simulation and Modelling
To further assess the impact of the mutation on the structure-conformation of the CCT5 subunit,
molecular dynamic simulation was carried out with the wild-type and the mutant CCT5 molecules.
They were compared under three forms: without ATP, with ATP, or with ADP (Figure 3).
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Figure 3. Protein conformational status for wild type and mutant CCT5 proteins. Image (A) is the 
superposition of the most probable conformations obtained from the molecular dynamics simulation 
of wild type CCT5 without nucleotide (gold), or bound to ATP (lilac), or bound to ADP (cyan). The 
image shows that the protein takes different conformations in the three conditions, especially at the 
level of the apical domain. Image (B) is the superposition of the most probable conformations 
obtained from the molecular dynamics simulation of mutant Leu224Val CCT5 without nucleotide 
Figure 3. Protein conformational status for wild type and mutant CCT5 proteins. Image (A) is the
superposition of the most probable conformations obtained from the molecular dynamics simulation
of wild type CCT5 without nucleotide (gold), or bound to ATP (lilac), or bound to ADP (cyan). The
image shows that the protein takes different conformations in the three conditions, especially at the
level of the apical domain. Image (B) is the superposition of the most probable conformations obtained
from the molecular dynamics simulation of mutant Leu224Val CCT5 without nucleotide (gold), or
bound to ATP (lilac), or bound to ADP (cyan). The image shows that the mutant protein takes different
conformations as compared with the wild type in the three conditions examined, especially at the level
of the apical domain.
The three forms were different for the wild-type molecule (Figure 3A) and for the mutant (Figure 3B),
and those of the latter were differed from those of the wild type, particularly the nucleotide-free form.
The apical domain of the nucleotide-free form of the mutant appears more relaxed than its counterpart
in the wild type. It is noteworthy that the apical domain changed the most, although, the affected
amino acid is in the intermediate domain.
3. Discussion
We describe a new disease affecting an Italian girl and characterized by early onset of severe
progressive neuropathy, daughter of consanguineous first-degree relatives. Trio-WES revealed an
homozygous c.670C>G p.(Leu224Val) missense variant in CCT5, which may play a pathogenic role.
Although the variant is formally classified as of uncertain significance, bioinformatics analyses
suggested a deleterious effect. The amino acid Leu224 is conserved not only in all vertebrates, but
also in distantly related species such as Drosophila, Caenorhabditis, and even Saccharomyces, supporting
the possibility of pathogenicity in its absence. Furthermore, in silico three-dimensional (3D) protein
structure analysis suggested that the Leu224Val change could affect the protein’s conformation. The
Leu224Val is located in the intermediate domain of the CCT5 subunit, but molecular dynamics
simulations suggest that the mutation may have an effect on the structure of the apical domain, which
could cause a global conformational alteration as it was observed for other mutations [7].
CCT functions as a hetero-oligomeric complex that consists of eight different subunits arranged
into octameric rings with a central cavity, which pair by their open sides to form hexadecamers with a
central chamber for protein folding [8,9]. The subunits are encoded by independent but evolutionarily
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related genes [10]. It has been estimated that as much as 10% of cytosolic proteins interact with the
eukaryotic chaperonin CCT along their folding pathways [11]. CCT is required for the folding of
essential proteins, including cytoskeletal proteins like tubulin and actin, as well as cell-cycle regulators
such as CDC20, and CDH1 [9,12]. Each CCT subunit consists of three structural domains: a) apical, for
substrate binding; b) equatorial, with ATP binding functions; and c) intermediate, for connecting the
other two domains. The CCT5 subunit has a specific function within the CCT complex: it hydrolyzes
ATP, working together with other neighboring subunits as a driver of energy for the whole complex [8].
The c.492A>G p.(His147Arg) variant in CCT5 has previously been described in four siblings of a
consanguineous Moroccan family showing an autosomal recessive mutilating sensory neuropathy
with spastic paraplegia [3,4]. This disease, and the one described here, possibly associated with the
variant p.(Leu224Val) share several neurological features, but also present peculiar differences that
may be attributed to the different effects of the two variants and/or other genetic and acquired factors
not yet identified.
Patients with the p.(His147Arg) have a severely impaired sensory function, especially affecting
lower limbs. This led to disfiguring lower-limb lesions and ultimately amputation. Our pro-band does
not show any sign of impaired sensory function, and no ulcerations are present in the upper or lower
limbs, nor in any other part of the body. In all patients with the p.(His147Arg) variant, motor function
was preserved, also in adulthood, when the patients were still autonomous in their movements.
Furthermore, they did not show any deterioration in cognitive and coordination functions. On the
other hand, our case showed significant motor impairments since the first year of life, which impeded
to reach the standing position or to walk. Currently, at seven years of age, she is not autonomous in
movements, respiration, and swallowing, and she is unable to communicate.
MRI revealed in patients with p.(His147Arg) an impaired myelination confined to the spinal
cord; EEGs were not available. In our pro-band, hypomyelination and demyelination signs are more
generalized as are the clinical signs and symptoms.
The skeletal system was normal in patients with p.(His147Arg); chest X-ray examination was not
done. Our case presents lumbar spinal scoliosis, which could be a direct effect of the disease and/or the
consequence of the severe hypotonia and predominant incorrect posture of a bedridden patient.
Patients with p.(His147Arg) had several biochemical abnormal parameters (hypotriglyceridemia,
hypocholesterolemia, and low levels of ApoB lipoprotein) but they are within the normal ranges in our
case (Table 1, Table 2 and Table S1).
Overall, all CCT5 p.(His147Arg) and p.(Leu224Val) cases present a neurologic disorder with
central nervous system myelin involvement. From a clinical point of view, the p.(His147Arg) appears
to be less aggressive and debilitating, involving mainly the sensory function. On the other hand, the
p.(Leu224Val) shows an early onset motor neuropathy with a progressive severe impairment. This new
variant could support the role for CCT5 in neurologic disorders and suggest that a wider phenotypical
spectrum of clinical manifestations may be associated with this gene.
4. Materials and Methods
4.1. Patients
The proband belongs to a large survey of pediatric syndromic cases collected at the Department
of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of
Palermo. Informed consent was collected from legal tutors (parents).
4.2. Motor Evoked Potentials
The patient was evaluated neurophysiologically with transcranial magnetic stimulation (TMS),
recording motor evoked potentials from muscles of the upper (i.e., abductor pollicis brevis (APB)
muscle) and lower (i.e., tibialis anterior (TA) muscle) limbs. A MagStim Rapid2 magnetic stimulator,
connected with a figure of eight coil of 70 mm diameter was used to measure motor-evoked potentials.
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For upper limb recordings, the coil was positioned over a left scalp position corresponding to C3 site
of the 10–20 EEG system. For lower limb recordings, the coil was positioned over a scalp position
located 3 cm anterior to the Cz site of the 10–20 EEG system. Surface electrodes were applied with a
belly-tendon montage on the APB muscle and on TA muscle. TMS intensity was gradually increased
until the maximal intensity of the stimulator was reached.
4.3. Motor Nerve Conduction Study
The right median nerve was stimulated supra maximally at the wrist and elbow, while the right
peroneal nerve was stimulated supra maximally at the ankle and head of the fibula through surface
electrodes. Compound muscle action potentials (CMAPs) were recorded through surface electrodes
placed over the APB muscle for the median nerve stimulation and over the extensor digitorum brevis
(EDB) muscle for the peroneal nerve stimulation. The CMAPs were amplified (frequency range 20
Hz–10 kHz) and latencies and amplitudes were measured off-line. The distal motor latency from wrist
to APB and from the ankle to EDB was measured and the motor nerve conduction velocity from elbow
to wrist and from fibula to ankle were calculated.
4.4. Sequencing
The family provided written informed consent for the molecular analyses. Whole exome
sequencing (WES) on the TRIO (proband, mother, and father) was performed using genomic DNA
extracted from circulating peripheral blood leukocytes, Figure 2. WES data processing, sequence
alignment to GRCh37, variant filtering and prioritization by allele frequency, predicted functional
impact, and inheritance models were performed using an in-house implemented pipeline, which
mainly takes advantage of the Genome Analysis Toolkit (GATK v.3.7), as previously described [6–13].
High-quality variants with an effect on the coding sequence or affecting splice site regions were
filtered against public databases (dbSNP150 and gnomAD V.2.0) to retain; (i) private and clinically
associated variants; and (ii) annotated variants with an unknown frequency or having minor allele
frequency < 0.1%, and occurring with a frequency < 2% in an in-house database including frequency
data from >1500 population-matched WES. The functional impact of variants was analyzed by CADD
V.1.3, Mendelian Clinically Applicable Pathogenicity V.1.0 [14,15], and using InterVar V.0.1.6 to obtain
clinical interpretation according to American College of Medical Genetics and Genomics/Association
for Molecular Pathology 2015 guidelines [16].
Based on consanguinity of the asymptomatic parents who were first degree cousins, we assumed an
autosomal recessive model of inheritance for the trait, and retained all the homozygous variants located
within LoH genomic stretches using Homozygosity Mapper [17] (http://www.homozygositymapper.
org), setting 80 as the number of consecutive homozygous SNPs. Variants were then filtered according
to their predicted functional impact, retaining those variants with CADD score > 15 [14,18], and then
prioritized considering the biological and clinical relevance of individual genes (HPO terms: Intellectual
disability, Microcephaly, Seizures, Muscular hypotonia). Sequence validation were performed by
Sanger sequencing using an ABI 3130XL and the ABI BigDye Terminator Sequencing Kit V 3.1, and
sequences were examined using the SeqScape v2.6 Software (Applied Biosystems, Foster City CA
94404 USA).
4.5. Molecular Dynamics Simulation and Modelling
The structural properties of the CCT5 subunit, wild type and mutated, were obtained starting
from the structure of the crystallized protein deposited in the Protein Data Bank with accession codes
5UYZ [19]. The structure of the mutant subunit was obtained by changing amino acid residue 224
Leucine with Valine, using the package Maestro Schrödinger LLC, New York, NY, 2018, version
11.6.010. Molecular dynamics (MD) simulations were performed for 150 ns (in some cases extended to
200ns), using the GROMACS 2018.3 package [20,21]. Interactions were described using an all-atoms
CHARMM27 force field [22,23].
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MD simulations for the various molecules and conditions were performed using a cubic box
of NaCl 150 mM in explicit TIP3P water solution. Periodic boundary conditions were applied.
The force field parameter files and initial configuration for the protein were created by GROMACS
utilities programs. The equilibration procedure was performed in several steps, starting from an NVT
(substance (N), volume (V) and temperature (T)) simulation at 300 K with the protein heavy atom
positions restrained to equilibrate the solvent around it, followed by a NPT (substance (N), pressure (P)
and temperature (T)) run at 300 K and pressure at 1 bar, for a 10 ns run. After the equilibration phase,
the system was run for a total of 150 ns (200 ns) for an NVT production run; the trajectory was saved at
a frequency of 10 ps to evaluate dynamical and structural properties. The MD simulations were always
checked versus the root mean square displacement (RMSD) and the energy profile (data not reported).
During the production runs a velocity rescaling thermostat [24] was used for the temperature coupling,
with a time coupling constant of 0.1 ps. A Parrinello–Rahman barostat [25] was used for the pressure
coupling, with relaxation constant of 1 ps. The equations of motion were integrated through the
Leap-Frog algorithm, using a 2 fs time step.
The values of cut-off of the Lennard-Jones and real space part of the Coulombic interactions were
set to 10 Å. The Particle Mesh Ewald (PME) summation method [26,27] was used to evaluate the
electrostatic interactions, with an interpolation order of 4 and 0.16 nm of FFT (Fast Fourier Transform)
grid spacing. The structures shown have been selected by clustering analysis [28–30] performed by the
g cluster tool implemented in GROMACS package, following the method outlined in [31]. Selected
images and protein manipulation were done using Maestro (Maestro, Schrödinger, version 11.6.010)
and CHIMERA [32]. All the simulations have been carried out on a workstation equipped with Intel
core I7 processor, 32 GB DDR3 system memory and Nvidia GeForce GTX 1080 TI GPU with 11GB
DDR5 memory.
5. Conclusions
Here, we describe a patient affected by early onset, demyelinating motor neuropathy, and the
presence of a homozygous variant c.670 C>G; p.(Leu224Val) in the gene encoding the subunit 5 of the
chaperonin CCT. Whether the mutation is the only cause of the disease in our patient, or a causative
factor among others, cannot be fully ascertained. Nevertheless, the Leu224Val variant seems to play a
pathogenic role because it is the only genetic abnormality we could detect that could have the effects
observed. Furthermore, the Leu224 is highly conserved in evolution, suggesting that it has a vital role
and that its change will have a serious negative impact on cell physiology. In silico analyses showed
that the mutation could induce conformational changes in the CCT5 molecule. If another family with
the same mutation is discovered, more data will become available for clarifying the role of this variant.
Meanwhile, the doors are open to continue research aiming at elucidating the impact of the Leu224Val
variant on the intrinsic properties and functions of the encoded chaperonin subunit and its role, if any,
in the mechanisms underpinning the tissue and organ lesions observed. In this regard, the availability
of another mutation, on the same CCT5 subunit but on a different structural domain and associated
with a different phenotype, offers a unique opportunity to elucidate the distinctive functions of the
various parts of a single chaperone molecule in health and in chaperonopathies.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/20/7631/s1,
Table S1: Biochemical data for both mutations. Table S2: Homozygous variants in proband.
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